A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
https://doi.org/10.4081/dr.2023.9722
HTML: 1
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
The development of flares or new-onset of immune-mediated dermatologic diseases, including psoriasis, has occurred with the worldwide spreading of the COVID-19 pandemic. We report the case of a 38-year-old woman who came to our department with a severe flare of plaque psoriasis four weeks after SARS-CoV-2 infection. Her Psoriasis Area Severity Index was 25, and her Dermatology Life Quality Index was 18. Our initial decision was to prescribe acitretin, but the patients reported adverse events. For this reason, we started risankizumab with complete skin clearance after 16 weeks. The patient is still on treatment, and no adverse events have been reported to date.
Wollina U, Karadağ AS, Rowland-Payne C et al. Cutaneous signs in COVID-19 patients: A review. Dermatol Ther. 2020 Sep;33(5):e13549. doi: 10.1111/dth.13549. Epub 2020 May 29. DOI: https://doi.org/10.1111/dth.13549
Aram K, Patil A, Goldust M et al. COVID-19 and exacerbation of dermatological diseases: A review of the available literature. Dermatol Ther. 2021 Nov;34(6):e15113. doi: 10.1111/dth.15113. DOI: https://doi.org/10.1111/dth.15113
Gargiulo L, Ibba L, Vignoli CA, et al. New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series, Journal of Dermatological Treatment, DOI: 10.1080/09546634.2023.2198050 DOI: https://doi.org/10.1080/09546634.2023.2198050
Bellinato F, Maurelli M, Gisondi P, Girolomoni G. Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines. J Clin Med. 2021 Nov 16;10(22):5344. doi: 10.3390/jcm10225344. DOI: https://doi.org/10.3390/jcm10225344
Pavia G, Gargiulo L, Spinelli F et al. Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e502-e505. DOI: https://doi.org/10.1111/jdv.18032
Awada B, Abdullah L, Kurban M, Abbas O. Comment on 'De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine': possible role for Type I interferons. Clin Exp Dermatol 2021 DOI: https://doi.org/10.1111/ced.14941
Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi: 10.1016/S0140-6736(18)31713-6. DOI: https://doi.org/10.1016/S0140-6736(18)31713-6
Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50-59. doi:10.1111/bjd.19341 DOI: https://doi.org/10.1111/bjd.19341
Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19?. J Am Acad Dermatol. 2020;82(5):1217-1218. doi:10.1016/j.jaad.2020.03.031 DOI: https://doi.org/10.1016/j.jaad.2020.03.031
Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) [published online ahead of print, 2022 Sep 26]. J Eur Acad Dermatol Venereol. 2022;10.1111/jdv.18594. doi:10.1111/jdv.18594 DOI: https://doi.org/10.1111/jdv.18594
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
